Press release
Giant-Cell Arteritis Market Outlook 2034: Key Epidemiological Shifts, Emerging Drugs, and Competitive Intelligence by DelveInsight
Giant-Cell Arteritis Market
Gain a deep understanding of the evolving Giant-Cell Arteritis landscape. Download DelveInsight's full report to explore market dynamics, pipeline developments, and upcoming treatment opportunities: Giant-Cell Arteritis Market Size - https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Highlights From the Giant-Cell Arteritis Market Report
• Novartis Pharmaceuticals announced on November 5, 2025, a study involving a screening phase of up to four weeks, a two-year treatment duration divided into two phases, followed by a 16-week treatment-free follow-up after the final secukinumab dose.
• In 2023, the United States accounted for 54% of all diagnosed prevalent GCA cases across the 7MM.
• Within the US, classic cranial GCA represented the majority of subtype-specific cases, followed by extracranial/large-vessel GCA.
• Among the EU4 and the UK, the United Kingdom reported the highest number of GCA cases, with Spain showing the lowest.
• In Japan, scalp tenderness was the most common clinical manifestation in 2023, with cases projected to rise through 2034.
• Leading companies shaping the GCA market include AbbVie, Novartis Pharmaceuticals, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG, among others.
• Promising therapies in development include Mavrilimumab, Prednisone, Baricitinib, and other novel candidates.
Stay ahead with detailed market intelligence and strategic insights. Explore more: Giant-Cell Arteritis Treatment Market Size - https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Giant-Cell Arteritis Epidemiology Segmentation (7MM)
• Giant-Cell Arteritis Diagnosed prevalent cases
• Giant-Cell Arteritis Region-specific cases
• Giant-Cell Arteritis Subtype-specific cases
• Giant-Cell Arteritis Gender-specific cases
• Giant-Cell Arteritis Age-specific cases
• Giant-Cell Arteritis Clinical manifestation-specific cases
• Total Giant-Cell Arteritis treated cases
Understand what drives epidemiology trends and future projections: Giant-Cell Arteritis Prevalence - https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Approved Therapies in Giant-Cell Arteritis
ACTEMRA/ROACTEMRA (tocilizumab) - Roche
A first-in-class anti-IL-6 receptor therapy targeting IL-6-mediated inflammatory pathways. By blocking IL-6, the treatment reduces inflammation, joint pain, and swelling. ACTEMRA/ROACTEMRA is approved for multiple inflammatory conditions, including GCA, pJIA, sJIA, RA, and CAR-T-induced CRS.
Emerging Therapies in the Pipeline
RINVOQ (upadacitinib) - AbbVie
An oral JAK inhibitor that modulates the JAK-STAT signaling pathway to reduce chronic inflammation. Already approved for several autoimmune diseases in the US, EU, and Japan, RINVOQ is being explored for GCA treatment.
COSENTYX (secukinumab) - Novartis Pharmaceuticals
A fully human anti-IL-17A monoclonal antibody approved for multiple autoimmune conditions, including psoriasis, AS, nr-axSpA, and PsA. It is under investigation for its potential role in GCA.
Explore future treatment innovations: Giant-Cell Arteritis Market Drivers & Barriers - https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Giant-Cell Arteritis Market Overview
GCA is named for the distinctive "giant" cells observed in arterial biopsies. While the exact cause remains unclear, research suggests a multifactorial origin involving genetics (HLA associations), immune dysregulation, environmental triggers, infection-related factors, and T-cell activation.
Giant-Cell Arteritis Treatment Landscape
The primary goal of therapy is to prevent severe complications, particularly vision loss. High-dose corticosteroids (40-60 mg daily) are typically prescribed for 3-4 weeks before tapering, although safety concerns persist. In certain cases, DMARDs such as methotrexate, leflunomide, or azathioprine are used to manage the disease or reduce steroid dependency.
Learn more about ongoing clinical research shaping the future of GCA management: Giant-Cell Arteritis Clinical Trials - https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Giant-Cell Arteritis Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Giant-Cell Arteritis Companies- AbbVie, Novartis Pharmaceuticals, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG, and others.
• Giant-Cell Arteritis Therapies- Mavrilimumab, Prednisone, Baricitinib, and others.
• Giant-Cell Arteritis Therapeutic Assessment: Giant-Cell Arteritis Current Marketed and Giant-Cell Arteritis Emerging Therapies
• Giant-Cell Arteritis Market Dynamics: Giant-Cell Arteritis market drivers and Giant-Cell Arteritis market barriers
• Giant-Cell Arteritis Unmet Needs, KOL's views, Analyst's views, Giant-Cell Arteritis Market Access and Reimbursement
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Giant-Cell Arteritis Market Outlook 2034: Key Epidemiological Shifts, Emerging Drugs, and Competitive Intelligence by DelveInsight here
News-ID: 4297306 • Views: …
More Releases from DelveInsight Business Research
Polycythemia Vera Pipeline and Drug Development in 2025: 10+ Therapies and 8+ Co …
DelveInsight's "Polycythemia Vera Pipeline Insight 2025" report delivers an in-depth overview of the Polycythemia Vera pipeline landscape, covering more than 8 companies and 10+ pipeline candidates. The report analyzes both clinical-stage and preclinical assets, offering detailed drug profiles across various stages of development. It also evaluates Polycythemia Vera therapies based on product classification, development stage, route of administration, and molecular category, while additionally spotlighting inactive or discontinued pipeline assets.
Explore the…
Myopic Macular Degeneration market across the 7MM is projected to reach USD 837 …
In 2022, the Myopic Macular Degeneration market across the 7MM was valued at approximately USD 734 million, largely driven by anti-VEGF therapies and standard care. The Myopic Macular Degeneration market is expected to grow gradually through 2034, constrained by a limited pipeline of emerging treatments. Japan accounts for the largest share of diagnosed cases (49%), followed by the United States (27%). Females are disproportionately affected across the 7MM, potentially due…
Netherton syndrome market across the 7MM was valued at approximately USD 25 mill …
The Netherton syndrome market is projected to grow at a 7% CAGR from 2025 to 2034, driven by key regions including the US, EU4, the UK, and Japan. In 2024, around 3,500 diagnosed prevalent cases were reported across the 7MM. Market expansion is primarily supported by advancing diagnostic capabilities, increasing disease awareness, rising diagnosis rates, and a strengthening clinical pipeline led by companies such as Azitra (ATR-12), Quoin Pharmaceuticals (QRX003),…
Sandhoff Disease Pipeline Analysis Highlights Emerging Therapies and Active Indu …
DelveInsight's "Sandhoff Disease Pipeline Insight 2025" report delivers an extensive overview of the Sandhoff Disease pipeline landscape, featuring insights on more than 5 companies and over 5 pipeline candidates. The report analyzes both clinical- and non-clinical-stage drug candidates, offering detailed profiles of Sandhoff Disease pipeline products. It also evaluates emerging therapeutics based on product category, development stage, route of administration, and molecular classification, while additionally highlighting inactive or discontinued pipeline…
More Releases for Arteritis
Giant Cell Arteritis Treatment Market: Global Trends, Growth, and Forecast 2025- …
The giant cell arteritis treatment market is witnessing significant traction with the increasing awareness of autoimmune disorders and the rising healthcare expenditure globally. The market, which was valued at USD 147.50 million in 2024, is projected to expand at a CAGR of 5.20% during the forecast period of 2025 to 2034, reaching a value of USD 244.88 million by 2034. With the growing geriatric population-particularly those above 50 years old-who…
Giant Cell Arteritis Treatment Market Size, Share, Industry Growth 2032
Giant Cell Arteritis Treatment Market Overview
Giant Cell Arteritis (GCA) is a systemic vasculitis condition that causes inflammation of the blood vessels, primarily affecting the large arteries in the head, such as the temporal arteries. The global Giant Cell Arteritis Treatment Market is driven by rising healthcare expenditure and increased awareness of autoimmune diseases. Treatments focus on reducing inflammation, controlling symptoms, and preventing complications, primarily using corticosteroids and other immunosuppressive therapies.…
Giant-Cell Arteritis Market Scope, Share, Trends Analysis And Forecasts(2024 - 2 …
"The Business Research Company recently released a comprehensive report on the Global Giant-Cell Arteritis Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
Giant-Cell Arteritis Market Size, Share Analysis And Growth Trends 2033
The new report published by The Business Research Company, titled Giant-Cell Arteritis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the giant-cell arteritis market size has grown steadily in recent years. It will grow from $1.02 billion in 2023…
Giant Cell Arteritis Therapeutics Market Forecast 2024-2030: Advances in Treatme …
Breakthrough Treatment for Giant Cell Arteritis Sparks Surge in Global Market Valuation
Giant Cell Arteritis, a prevalent form of systemic vasculitis affecting individuals over 50, is witnessing a paradigm shift in its treatment landscape. The condition, characterized by granulomatous medium and large-vessel inflammation, is most common among Caucasians, particularly those in Scandinavian countries and of northern European descent. However, the European market is anticipated to experience accelerated growth, challenging previous demographic…
Global Giant Cell Arteritis Treatment Market Forecast 2023-2028 Under Inflation
This Giant Cell Arteritis Treatment market report assists major companies in generating revenues by making the appropriate investments and taking the necessary actions to alter perceptions. It addresses compliance hurdles as well as future possibilities as a whole. By adhering to these business indicators, industries may create goals for their businesses, overcome the competition, follow strategic goals, and, as a result, make large profits. It allows businesses to take a…
